Skip to main
SNTI

SNTI Stock Forecast & Price Target

SNTI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Senti Biosciences Inc. is poised for a positive outlook due to the successful performance of its product candidate SENTI-202, which has demonstrated statistically significant anti-tumor activity in preclinical models, indicating strong potential for efficacy in treating acute myeloid leukemia. The company's innovative use of allogeneic CAR-NK cells presents a favorable safety profile compared to traditional CAR-T therapies, positioning SENTI-202 strategically within a competitive landscape with limited offerings for similar therapies. Furthermore, the granting of orphan drug designation (ODD) suggests not only a promising regulatory pathway but also enhanced support from the FDA, which could facilitate expedited development and eventual market entry, reinforcing confidence in the company's clinical trajectory as it approaches critical data updates in late 2025.

Bears say

Senti Biosciences Inc faces several fundamental challenges contributing to a negative outlook on its stock. Key risks include potential safety concerns emerging from clinical programs, lower-than-expected efficacy results, and significant competition within the biotechnology sector, which could hinder the commercialization of its therapies. Additionally, the company requires substantial financing to maintain operations through 2040, raising concerns about its financial health and sustainability, especially given its current market capitalization of approximately $47 million, which is notably lower than its competitors in the allogeneic cell therapy space.

SNTI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Senti Biosciences Inc (SNTI) Forecast

Analysts have given SNTI a Strong Buy based on their latest research and market trends.

According to 4 analysts, SNTI has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Senti Biosciences Inc (SNTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.